Valsartan	valsartan	O	O
,	,	O	O
a	a	O	O
new	new	O	O
angiotensin	angiotensin	B_chemical	O
II	ii	I_chemical	O
antagonist	antagonist	O	O
for	for	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
essential	essential	O	B_disease
hypertension	hypertension	O	S_disease
:	:	O	O
a	a	O	O
comparative	comparative	O	O
study	study	O	O
of	of	O	O
the	the	O	O
efficacy	efficacy	O	O
and	and	O	O
safety	safety	O	O
against	against	O	O
amlodipine	amlodipine	O	O
.	.	O	O

OBJECTIVE	objective	O	O
:	:	O	O
To	to	O	O
compare	compare	O	O
the	the	O	O
antihypertensive	antihypertensive	O	O
efficacy	efficacy	O	O
of	of	O	O
a	a	O	O
new	new	O	O
angiotensin	angiotensin	B_chemical	O
II	ii	I_chemical	O
antagonist	antagonist	O	O
,	,	O	O
valsartan	valsartan	O	O
,	,	O	O
with	with	O	O
a	a	O	O
reference	reference	O	O
therapy	therapy	O	O
,	,	O	O
amlodipine	amlodipine	O	O
.	.	O	O

METHODS	methods	O	O
:	:	O	O
One	one	O	O
hundred	hundred	O	O
sixty-eight	sixty-eight	O	O
adult	adult	O	O
outpatients	outpatients	O	O
with	with	O	O
mild	mild	O	O
to	to	O	O
moderate	moderate	O	O
hypertension	hypertension	O	S_disease
were	were	O	O
randomly	randomly	O	O
allocated	allocated	O	O
in	in	O	O
double-blind	double-blind	O	O
fashion	fashion	O	O
and	and	O	O
equal	equal	O	O
number	number	O	O
to	to	O	O
receive	receive	O	O
80	80	O	O
mg	mg	O	O
valsartan	valsartan	O	O
or	or	O	O
5	5	O	O
mg	mg	O	O
amlodipine	amlodipine	O	O
for	for	O	O
12	12	O	O
weeks	weeks	O	O
.	.	O	O

After	after	O	O
8	8	O	O
weeks	weeks	O	O
of	of	O	O
therapy	therapy	O	O
,	,	O	O
in	in	O	O
patients	patients	O	O
whose	whose	O	O
blood	blood	O	O
pressure	pressure	O	O
remained	remained	O	O
uncontrolled	uncontrolled	O	O
,	,	O	O
5	5	O	O
mg	mg	O	O
amlodipine	amlodipine	O	O
was	was	O	O
added	added	O	O
to	to	O	O
the	the	O	O
initial	initial	O	O
therapy	therapy	O	O
.	.	O	O

Patients	patients	O	O
were	were	O	O
assessed	assessed	O	O
at	at	O	O
4	4	O	O
,	,	O	O
8	8	O	O
,	,	O	O
and	and	O	O
12	12	O	O
weeks	weeks	O	O
.	.	O	O

The	the	O	O
primary	primary	O	O
efficacy	efficacy	O	O
variable	variable	O	O
was	was	O	O
change	change	O	O
from	from	O	O
baseline	baseline	O	O
in	in	O	O
mean	mean	O	O
sitting	sitting	O	O
diastolic	diastolic	O	O
blood	blood	O	O
pressure	pressure	O	O
at	at	O	O
8	8	O	O
weeks	weeks	O	O
.	.	O	O

Secondary	secondary	O	O
variables	variables	O	O
included	included	O	O
change	change	O	O
in	in	O	O
sitting	sitting	O	O
systolic	systolic	O	O
blood	blood	O	O
pressure	pressure	O	O
and	and	O	O
responder	responder	O	O
rates	rates	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
Both	both	O	O
valsartan	valsartan	O	O
and	and	O	O
amlodipine	amlodipine	O	O
were	were	O	O
effective	effective	O	O
at	at	O	O
lowering	lowering	O	O
blood	blood	O	O
pressure	pressure	O	O
at	at	O	O
4	4	O	O
,	,	O	O
8	8	O	O
,	,	O	O
and	and	O	O
12	12	O	O
weeks	weeks	O	O
.	.	O	O

Similar	similar	O	O
decreases	decreases	O	O
were	were	O	O
observed	observed	O	O
in	in	O	O
both	both	O	O
groups	groups	O	O
,	,	O	O
with	with	O	O
no	no	O	O
statistically	statistically	O	O
significant	significant	O	O
differences	differences	O	O
between	between	O	O
the	the	O	O
groups	groups	O	O
for	for	O	O
any	any	O	O
variable	variable	O	O
analyzed	analyzed	O	O
.	.	O	O

For	for	O	O
the	the	O	O
primary	primary	O	O
variable	variable	O	O
the	the	O	O
difference	difference	O	O
was	was	O	O
0.5	0.5	O	O
mm	mm	O	O
Hg	hg	O	O
in	in	O	O
favor	favor	O	O
of	of	O	O
valsartan	valsartan	O	O
(	(	O	O
p	p	O	O
=	=	O	O
0.68	0.68	O	O
;	;	O	O
95	95	O	O
%	%	O	O
confidence	confidence	O	O
interval	interval	O	O
,	,	O	O
-2.7	-2.7	O	O
to	to	O	O
1.7	1.7	O	O
)	)	O	O
.	.	O	O

Responder	responder	O	O
rates	rates	O	O
at	at	O	O
8	8	O	O
weeks	weeks	O	O
were	were	O	O
66.7	66.7	O	O
%	%	O	O
for	for	O	O
valsartan	valsartan	O	O
and	and	O	O
60.2	60.2	O	O
%	%	O	O
for	for	O	O
amlodipine	amlodipine	O	O
(	(	O	O
p	p	O	O
=	=	O	O
0.39	0.39	O	O
)	)	O	O
.	.	O	O

Both	both	O	O
treatments	treatments	O	O
were	were	O	O
well	well	O	O
tolerated	tolerated	O	O
.	.	O	O

The	the	O	O
incidence	incidence	O	O
of	of	O	O
drug-related	drug-related	O	O
dependent	dependent	O	O
edema	edema	O	S_disease
was	was	O	O
somewhat	somewhat	O	O
higher	higher	O	O
in	in	O	O
the	the	O	O
amlodipine	amlodipine	O	O
group	group	O	O
,	,	O	O
particularly	particularly	O	O
at	at	O	O
a	a	O	O
dose	dose	O	O
of	of	O	O
10	10	O	O
mg	mg	O	O
per	per	O	O
day	day	O	O
(	(	O	O
2.4	2.4	O	O
%	%	O	O
for	for	O	O
80	80	O	O
mg	mg	O	O
valsartan	valsartan	O	O
;	;	O	O
3.6	3.6	O	O
%	%	O	O
for	for	O	O
5	5	O	O
mg	mg	O	O
amlodipine	amlodipine	O	O
;	;	O	O
0	0	O	O
%	%	O	O
for	for	O	O
valsartan	valsartan	O	O
plus	plus	O	O
5	5	O	O
mg	mg	O	O
amlodipine	amlodipine	O	O
;	;	O	O
14.3	14.3	O	O
%	%	O	O
for	for	O	O
10	10	O	O
mg	mg	O	O
amlodipine	amlodipine	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
The	the	O	O
data	data	O	O
show	show	O	O
that	that	O	O
valsartan	valsartan	O	O
is	is	O	O
at	at	O	O
least	least	O	O
as	as	O	O
effective	effective	O	O
as	as	O	O
amlodipine	amlodipine	O	O
in	in	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
mild	mild	O	O
to	to	O	O
moderate	moderate	O	O
hypertension	hypertension	O	S_disease
.	.	O	O

The	the	O	O
results	results	O	O
also	also	O	O
show	show	O	O
valsartan	valsartan	O	O
to	to	O	O
be	be	O	O
well	well	O	O
tolerated	tolerated	O	O
and	and	O	O
suggest	suggest	O	O
that	that	O	O
it	it	O	O
is	is	O	O
not	not	O	O
associated	associated	O	O
with	with	O	O
side	side	O	O
effects	effects	O	O
characteristic	characteristic	O	O
of	of	O	O
this	this	O	O
comparator	comparator	O	O
class	class	O	O
,	,	O	O
dihydropyridine	dihydropyridine	O	O
calcium	calcium	S_chemical	O
antagonists	antagonists	O	O
.	.	O	O

